Cardiff Oncology (CRDF)
(Delayed Data from NSDQ)
$3.48 USD
+0.09 (2.65%)
Updated May 13, 2024 04:00 PM ET
After-Market: $3.49 +0.01 (0.29%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Cardiff Oncology, Inc. [CRDF]
Reports for Purchase
Showing records 21 - 27 ( 27 total )
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
All Eyes on Onvansertib; 1Q21 Financial Results; Modulating PT to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Favorable Yet Preliminary Onvansertib Combo Data in KRAS+ mCRC; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
2020 Financial Results; Awaiting Additional Onvansertib Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Onvansertib Optimized Dosing Appears to Sustain Zytiga Efficacy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Despite a Slight ORR Decline, We Await Onvansertib PFS Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Looking Ahead to ASCO GI Data; Strong Cash Position; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Potently Picking off Polo-Like Kinase 1; Initiating at Buy and $27 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R